Discovery of Potent and Selective MNK Kinase Inhibitors for the Treatment of Leukemia

Area of Science:

• Biochemistry
• Oncology
• Medicinal Chemistry

Background:

• Mitogen-activated protein kinase (MAPK)-interacting kinase (MNK) activity is regulated by p38 and Erk MAPK pathways.
• Activated MNK phosphorylates eukaryotic initiation factor 4E (eIF4E) at Ser209, promoting oncogene translation and tumorigenesis.
• Acute myeloid leukemia (AML) remains an area of significant unmet medical need.

Purpose of the Study:

• To develop novel small molecule inhibitors targeting MNK for potential AML therapy.
• To evaluate the efficacy of these inhibitors in reducing leukemia cell viability and colony formation.
• To confirm the binding mode of inhibitors via X-ray crystallography for future optimization.

Main Methods:

• Medicinal optimization of novel small molecule inhibitors.
• Evaluation of inhibitor effects on eIF4E phosphorylation and leukemia cell viability.
• X-ray cocrystallization to determine inhibitor binding modes.

Main Results:

• Discovery of a class of ether-containing compounds with high MNK1/2 selectivity.
• Demonstrated potency of MNK inhibitors in reducing leukemia cell viability and colony formation.
• Established desirable pharmacokinetic properties for the developed inhibitors.

Conclusions:

• MNK inhibition represents a promising therapeutic strategy for AML.
• The novel MNK inhibitors exhibit potent anti-leukemic effects and favorable drug-like properties.
• Structural insights from X-ray crystallography will guide further optimization of these inhibitors.